 Hookipa Pharma Inc NASDAQ: HOOK reported positive Phase 1 data from its ongoing Phase 12 study evaluating HB-200 to treat advanced Human Papillomavirus 16-positive HPV16 cancers. Data were presented at the 2021 American Society of Clinical Oncology ASCO Annual Meeting. 